ArticleJournal of inflammation research2025
Semaphorin 6D Alleviates Osteoarthritis by Inhibiting NLRP3 Inflammasome Activation and Endoplasmic Reticulum Stress.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Osteoarthritis (OA) is a degenerative joint disease that affects over 500 million individuals globally, characterized by the degradation of cartilage, subchondral bone sclerosis, and synovitis. A key factor in the progression of OA is synovial inflammation, which is driven by macrophage polarization and inflammasome activation. This inflammation exacerbates cartilage degradation, creating a vicious cycle that accelerates disease progression. Targeting macrophage activity presents a promising therapeutic strategy to alleviate the symptoms and progression of OA. Methods: To investigate the role of SEMA6D in macrophage polarization and its potential therapeutic implications for OA, we conducted transcriptomic analysis to explore its regulatory functions. In vitro experiments were performed to assess the effects of SEMA6D overexpression on the expression of ASC and NLRP3, as well as on macrophage (RAW264.7) polarization toward the pro-inflammatory M1 phenotype. In vivo studies were conducted using an OA rat model to evaluate the influence of SEMA6D overexpression on synovial macrophage polarization and the levels of inflammatory mediators, including IL-1β and IL-6. Results: Our transcriptomic analysis indicated that SEMA6D plays a regulatory role in macrophage polarization. Overexpression of SEMA6D resulted in the downregulation of ASC and NLRP3, effectively inhibiting the polarization of macrophages toward the M1 phenotype and downregulate the expression levels of iNOS and IL-6 by more than twofold. In the DMM rat model, SEMA6D overexpression significantly reduced the polarization of synovial macrophages to the M1 phenotype, leading to lower levels of inflammatory mediators such as IL-1β and IL-6, and mitigating cartilage degeneration. Conclusion: SEMA6D exerts a protective effect against OA by attenuating synovial macrophage-mediated inflammatory responses through the inhibition of NLRP3 inflammasome activation and endoplasmic reticulum stress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.